Complying with REMS Training and Documentation Requirements

Michael Singel, PharmD, discusses the logistics of complying with the Risk Evaluation and Mitigation Strategy program for bispecific antibodies at his institution and addresses training and documentation requirements.

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

Now Viewing

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

Related Videos

Related Content

Advertisement

April 30th 2025

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Alana Hippensteele, Lead Editor

January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

April 4th 2025

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

Alexandra Gerlach, Associate Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor

March 21st 2025

BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement

Alexandra Gerlach, Associate Editor

Related Content

Advertisement

April 30th 2025

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Alana Hippensteele, Lead Editor

January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

April 4th 2025

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

Alexandra Gerlach, Associate Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor

March 21st 2025

BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement

Alexandra Gerlach, Associate Editor